Discover
ARWR
Arrowhead Pharmaceuticals, Inc.
80.44
2 x 75.26
2 x 87.79
bid
ask
-
1.07
1.31%
2 @ 06:03 AM
81.00 +0.56 (0.70%)
| Ytd | 21.16% | |
| 1y | 399.94% |
78.81
day range
82.39
14.30
52 week range
84.55
| Open | 82.28 | Prev Close | 81.51 | Low | 78.81 | High | 82.39 | Mkt Cap | 11.33B |
| Vol | 1.93M | Avg Vol | 2.03M | EPS | -2.27 | P/E | N/A | Forward P/E | -18.55 |
| Beta | 1.27 | Short Ratio | 7.88 | Inst. Own | 88.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 76.20 | 200-d Avg | 60.19 | 1yr Est | 89.08 |
| Income Statement | |||
| Total Revenue | 73.74M | ||
| Revenues (USD) | 73.74M | ||
| Gross Profit | 73.74M | ||
| Operating Expenses | 215.00M | ||
| Research and Development Expense | 173.25M | ||
| Selling, General and Administrative Expense | 41.74M | ||
| Operating Income | -141.26M | ||
| Interest Expense | 23.85M | ||
| Income Tax Expense | 7.00K | ||
| Net Income | -132.73M | ||
| Net Income Common Stock | -132.73M | ||
| Net Income Common Stock (USD) | -132.73M | ||
| Consolidated Income | -137.57M | ||
| Net Income to Non-Controlling Interests | -4.84M | ||
| Earnings per Basic Share | -0.93 | ||
| Earnings per Basic Share (USD) | -0.93 | ||
| Earnings per Diluted Share | -0.93 | ||
| Earning Before Interest & Taxes (EBIT) | -108.88M | ||
| Earning Before Interest & Taxes (USD) | -108.88M | ||
| Weighted Average Shares | 142.42M | ||
| Weighted Average Shares Diluted | 142.42M | ||
| Balance Sheet | |||
| Cash and Equivalents | 188.52M | ||
| Cash and Equivalents (USD) | 188.52M | ||
| Investments | 1.60B | ||
| Investments Current | 1.60B | ||
| Trade and Non-Trade Receivables | 15.69M | ||
| Current Assets | 1.84B | ||
| Property, Plant & Equipment Net | 417.62M | ||
| Total Assets | 2.27B | ||
| Debt Current | 47.77M | ||
| Total Debt | 1.37B | ||
| Current Liabilities | 295.22M | ||
| Debt Non-Current | 1.33B | ||
| Total Liabilities | 1.67B | ||
| Accumulated Retained Earnings (Deficit) | -1.73B | ||
| Accumulated Other Comprehensive Income | 742.00K | ||
| Shareholders Equity | 613.98M | ||
| Shareholders Equity (USD) | 613.98M | ||
| Assets Non-Current | 428.51M | ||
| Total Debt (USD) | 1.37B | ||
| Deferred Revenue | 157.16M | ||
| Goodwill and Intangible Assets | 6.01M | ||
| Liabilities Non-Current | 1.37B | ||
| Trade and Non-Trade Payables | 30.75M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 6.37M | ||
| Net Cash Flow from Financing | 795.72M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -14.12M | ||
| Capital Expenditure | -2.56M | ||
| Issuance (Purchase) of Equity Shares | 221.65M | ||
| Issuance (Repayment) of Debt Securities | 663.46M | ||
| Net Cash Flow from Investing | -894.28M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -891.72M | ||
| Net Cash Flow from Operations | 84.44M | ||
| Effect of Exchange Rate Changes on Cash | 997.00K | ||
| Share Based Compensation | 16.67M | ||